Zobrazeno 1 - 10
of 2 105
pro vyhledávání: '"CRPC"'
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 1267-1283 (2024)
Bicky Thapa,1,* Navonil De Sarkar,2– 4,* Subhajit Giri,2,3 Komal Sharma,2– 4 Mingee Kim,5 Deepak Kilari1 1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 2Medical College of Wisconsin Cancer Center,
Externí odkaz:
https://doaj.org/article/7099d4bb6250439690b805dadd42278b
Autor:
Jiajia Wang, Hui Liu, Zeyuan Yu, Qianqian Zhou, Feifei Sun, Jingying Han, Lin Gao, Baokai Dou, Hanwen Zhang, Jiawei Fu, Wenqiao Jia, Weiwen Chen, Jing Hu, Bo Han
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Endocrine resistance driven by sustained activation of androgen receptor (AR) signaling pathway in advanced prostate cancer (PCa) is fatal. Characterization of mechanisms underlying aberrant AR pathway activation to search for pot
Externí odkaz:
https://doaj.org/article/53f2bb0e165443118786ddd413f4b43e
Autor:
Yuanyuan Wang, Jiyuan Chen, Luyao Gong, Yunxia Wang, Aino Siltari, Yan-Ru Lou, Teemu J. Murtola, Shen Gao, Yuan Gao
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Resistance to androgen receptor (AR) inhibitors, including enzalutamide (Enz), as well as bone metastasis, are major challenges for castration-resistant prostate cancer (CRPC) treatment. In this study, we identified that miR26a can restore E
Externí odkaz:
https://doaj.org/article/d27180e3a2634eff9bbb371e72a61484
Autor:
Yicong Yao, Qinghua Wang, Wei Jiang, Haopeng Li, Xilei Li, Tong Zi, Xin Qin, Yan Zhao, Denglong Wu, Gang Wu
Publikováno v:
Heliyon, Vol 10, Iss 18, Pp e37075- (2024)
Prostate cancer is a significant contributor to cancer-related mortality, and the tumor typically develops into castration-resistant prostate cancer (CRPC). Hence, few effective clinical strategies are available to patients with advanced disease. Ext
Externí odkaz:
https://doaj.org/article/6caa6287162040db912431a21c059266
Publikováno v:
Journal of Men's Health, Vol 20, Iss 3, Pp 113-120 (2024)
Prostate cancer (PC) has risen to become the second most common neoplasm in men, trailing only lung cancer. Individuals with advanced prostate cancer, particularly those who are resistant to androgen deprivation therapy (ADT), also known as castratio
Externí odkaz:
https://doaj.org/article/660c825b3f874bdd85e2062371d155da
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/877b7439e6fb403fbe50735d7b242457
Autor:
Xiang Gao, Haolin Zhao, Jiao Liu, Min Wang, Zhihong Dai, Wenjun Hao, Yanlong Wang, Xiang Wang, Min Zhang, Pixu Liu, Hailing Cheng, Zhiyu Liu
Publikováno v:
Advanced Science, Vol 11, Iss 30, Pp n/a-n/a (2024)
Abstract Despite the initial efficacy of enzalutamide in castration‐resistant prostate cancer (CRPC), inevitable resistance remains a significant challenge. Here, the synergistic induction of copper‐dependent cell death (cuproptosis) in CRPC cell
Externí odkaz:
https://doaj.org/article/febbb203e9aa4735a6e1ac2e1ad2be88
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/d8932bafd25946afb29651e3b0142145
Publikováno v:
Pharmacological Research, Vol 205, Iss , Pp 107234- (2024)
After the initial androgen deprivation therapy (ADT), part of the prostate cancer may continuously deteriorate into castration-resistant prostate cancer (CRPC). The majority of patients suffer from the localized illness at primary diagnosis that coul
Externí odkaz:
https://doaj.org/article/364ce6bf959a46618f61dcba2c1d960b
Autor:
Richard Weiten, Max Niemann, Eduard Below, Lea L. Friker, Damian J. Ralser, Marieta Toma, Glen Kristiansen, Oliver Hahn, Sabrina Zechel, Viktor Grünwald, Tobias Bald, Johannes Siewert, Torsten Pietsch, Manuel Ritter, Michael Hölzel, Markus Eckstein, Abdullah Alajati, Philipp Krausewitz, Niklas Klümper
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Purpose Improved survival rates have been observed in castration‐resistant prostate cancer (CRPC) due to advancements in treatment options. However, individuals with brain metastases still have limited therapeutic options and an unfavorabl
Externí odkaz:
https://doaj.org/article/296319f737d046debd441f74e94d7c29